All In Biotech

Drug Trial Radar · NCT06120491

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,898 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,898

Actual

Start

Nov 21, 2023

Primary completion

Sep 30, 2027

Study completion Apr 30, 2031

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Conditions

  • Metastatic Castration-Sensitive Prostate Cancer

Interventions

  • SaruparibDrug

    Oral

  • PlaceboDrug

    Oral

  • Abiraterone AcetateDrug

    Oral

  • DarolutamideDrug

    Oral

  • EnzalutamideDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-Free Survival (rPFS)Time frame: Up to approximately 50 months

Locations

322 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Gilbert, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Springdale, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Fullerton, California

  • Research Site

    Los Angeles, California

  • Research Site

    Montebello, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Barbara, California

  • Research Site

    Santa Monica, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Golden, Colorado

  • Research Site

    Lakewood, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Atlanta, Georgia

  • Research Site

    Glenview, Illinois

  • Research Site

    Lake Barrington, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Westwood, Kansas

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Scarborough, Maine

  • Research Site

    Baltimore, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Bethesda, Maryland

  • Research Site

    Towson, Maryland

  • Research Site

    Upper Marlboro, Maryland

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Troy, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    Bozeman, Montana

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Camden, New Jersey

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    East Syracuse, New York

Showing 40 of 322 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.